跳至主要内容
临床试验/ISRCTN02543559
ISRCTN02543559已完成1 期

A phase 1 study to investigate the effect of single and repeated doses of DSP-2230/placebo on renal function in healthy subjects

Sunovion Pharmaceuticals Europe Ltd (UK)0 个研究点目标入组 44 人开始时间: 2013年11月12日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. All subjects (males) will be in good health aged = 18 and = 55 years with no evidence of systemic disease
  • 2. Be able to comply with all aspects of the protocol
  • 3. Able to give written informed consent to participate in the study

排除标准

  • 1. All subjects will not have, or have had a history of, clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological or other major disorders
  • 2. They will not have, or have had a history of, drug or alcohol abuse
  • 3. Will not have participated in a clinical study with an investigational medicinal product (IMP) within 3 months of randomisation into the current study
  • 4. Will not have donated or lost >500 mL of blood or blood products in the 3 months preceding the start of dosing

研究者

发起方
Sunovion Pharmaceuticals Europe Ltd (UK)

相似试验